Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
复制标题
DOI：
10.3324/haematol.2009.015073
复制
发表时间：
2010-05-01
期刊：
影响因子：
--
通讯作者：
Gonzalez, Marcos
中科院分区：
文献类型：
--
作者：
Carmen Chillon, Maria;Santamaria, Carlos;Gonzalez, Marcos
FLT 3基因的内部串联重复FLT 3-ITD突变在急性早幼粒细胞白血病（APL）患者中很常见，但其临床影响仍存在争议。设计和方法我们分析了FLT 3-ITD突变水平和大小以及FLT 3-D835点突变的预后意义，在西班牙LPA 96（n=43）或LPA 99（n=86）PETHEMA试验中入选的129例APL患者中，PML-RAR α表达和其他预测因素。在21%和9%的患者中分别检测到ITD和D835突变。ITD突变型/野生型比例增加或ITD大小较长的患者显示较短的5年无复发生存期（RFS）（P=0.048和P
BackgroundInternal tandem duplications of the FLT3 gene (FLT3-ITDs) are frequent in patients with acute promyelocytic leukemia (APL), however its clinical impact remains controversial.Design and MethodsWe analyzed the prognostic significance of FLT3-ITD mutant level and size, as well as FLT3-D835 point mutations, PML-RAR alpha expression and other predictive factors in 129 APL patients at diagnosis enrolled on the Spanish LPA96 (n=43) or LPA99 (n=86) PETHEMA trials.ResultsFLT3-ITDs and D835 mutations were detected in 21% and 9% of patients, respectively. Patients with increased ITD mutant/wild-type ratio or longer ITD size displayed shorter 5-year relapse-free survival (RFS) (P=0.048 and P